Insulin Receptor Substrate-1 (IRS-1) and IRS-2 expression levels are associated with prognosis in non-small cell lung cancer (NSCLC)

Identification of novel mutations of Insulin Receptor Substrate 1 (IRS1) in tumor samples of non-small cell lung cancer (NSCLC): Implications for aberrant insulin signaling in development of cancer

(2019) Gokhan Gorgisen et al.   GENETICS AND MOLECULAR BIOLOGY

Insulin receptor substrate-1 deficiency drives a proinflammatory phenotype inKRASmutant lung adenocarcinoma

(2016) Heather E. Metz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations

(2015) Chang Dong Yeo et al.   LUNG CANCER

Comprehensive genomic profiles of small cell lung cancer

(2015) Julie George et al.   NATURE

The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor

(2014) Kenichi Suda et al.   INTERNATIONAL JOURNAL OF CANCER

Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer

(2014) Christine M Lovly et al.   NATURE MEDICINE

Hypoxia Increases Gefitinib-Resistant Lung Cancer Stem Cells through the Activation of Insulin-Like Growth Factor 1 Receptor

(2014) Akiko Murakami et al.   PLoS One

Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS

(2014) Grzegorz J. Korpanty et al.   Frontiers in Oncology

Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients

(2013) V. Ludovini et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors

(2013) Holly A. Porter et al.   CANCER LETTERS

High Coexpression of Both EGFR and IGF1R Correlates With Poor Patient Prognosis in Resected Non–Small-Cell Lung Cancer

(2013) Kathy Gately et al.   Clinical Lung Cancer

Comprehensive genomic characterization of squamous cell lung cancers

(2012)   NATURE

Insulin Receptor Isoforms A and B as well as Insulin Receptor Substrates-1 and -2 Are Differentially Expressed in Prostate Cancer

(2012) Martin Heni et al.   PLoS One

Membrane localization of insulin receptor substrate-2 (IRS-2) is associated with decreased overall survival in breast cancer

(2011) Jennifer L. Clark et al.   BREAST CANCER RESEARCH AND TREATMENT

Insulin receptor substrates form high-molecular-mass complexes that modulate their availability to insulin/insulin-like growth factor-I receptor tyrosine kinases

(2010) Toshiaki Fukushima et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Insulin Receptor Substrate-1 Suppresses Transforming Growth Factor- 1-Mediated Epithelial-Mesenchymal Transition

(2009) J. Shi et al.   CANCER RESEARCH

Expression and function of the insulin receptor substrate proteins in cancer

(2009) Katerina Mardilovich et al.   Cell Communication and Signaling

Irs2 Inactivation Suppresses Tumor Progression in Pten+/− Mice

(2008) Matthias Szabolcs et al.   AMERICAN JOURNAL OF PATHOLOGY

Insulin Receptor Substrate-2 Regulates Aerobic Glycolysis in Mouse Mammary Tumor Cells via Glucose Transporter 1

(2008) Shannon L. Pankratz et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Somatic mutations affect key pathways in lung adenocarcinoma

(2008) Li Ding et al.   NATURE